Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
Turn Therapeutics (Nasdaq: TTRX) launched a shareholder communications initiative including a recurring webinar series and a Founder Blog by CEO Bradley Burnam.
The first live webinar is scheduled for October 22, 2025 at 2:00 PM ET via webcast; recordings and materials will be posted to the investor relations website immediately after each session. The Founder Blog will share ongoing company updates, research insights, and perspectives, with additional blog details to be announced later this week.
Turn notes three FDA clearances for its wound and dermatology formulations and ongoing late-stage clinical programs in eczema and onychomycosis.
Turn Therapeutics (Nasdaq: TTRX) ha avviato un'iniziativa di comunicazione agli azionisti che include una serie ricorrente di webinar e un Blog del Fondatore scritto dal CEO Bradley Burnam.
Il primo webinar dal vivo è previsto per 22 ottobre 2025 alle 14:00 ET via webcast; le registrazioni e i materiali saranno pubblicati sul sito degli investitori subito dopo ogni sessione. Il Blog del Fondatore condividerà aggiornamenti continui dell'azienda, approfondimenti di ricerca e prospettive, con ulteriori dettagli sul blog annunciati entro la fine della settimana.
Turn segnala tre autorizzazioni FDA per le sue formulazioni per ferite e dermatologia e programmi clinici in fase avanzata in eczema e onicomicosi.
Turn Therapeutics (Nasdaq: TTRX) lanzó una iniciativa de comunicación con los accionistas que incluye una serie de seminarios web recurrentes y un Blog del Fundador del CEO Bradley Burnam.
El primer seminario web en vivo está programado para el 22 de octubre de 2025 a las 2:00 PM ET a través de webcast; las grabaciones y el material se publicarán en el sitio web de relaciones con inversionistas inmediatamente después de cada sesión. El Blog del Fundador compartirá actualizaciones continuas de la empresa, ideas de investigación y perspectivas, con más detalles del blog que se anunciarán más adelante esta semana.
Turn señala tres aprobaciones de la FDA para sus formulaciones de heridas y dermatología y programas clínicos en etapa avanzada para eczema y onicomicrosis.
Turn Therapeutics (나스닥: TTRX)는 주주 커뮤니케이션 이니셔티브를 시작했으며, 정기 웹세미나 시리즈와 CEO Bradley Burnam의 창립자 블로그를 포함합니다.
첫 번째 라이브 웹세미나가 2025년 10월 22일 오후 2:00 ET에 webcast로 예정되어 있습니다. 각 세션 직후 투자자 관계 웹사이트에 녹화본과 자료가 게시될 예정입니다. 창립자 블로그는 지속적인 회사 소식, 연구 통찰 및 관점을 공유하며, 블로그의 추가 세부 내용은 이번 주에 추후 공지될 예정입니다.
Turn은 상처 치료 및 피부과 포뮬레이션에 대한 FDA 세 가지 인가를 언급하고, 습진과 조갑증에 대한 최종 단계 임상 프로그램을 진행 중입니다.
Turn Therapeutics (Nasdaq: TTRX) a lancé une initiative de communication avec les actionnaires comprenant une série de webinaires récurrents et un Blog du Fondateur par le PDG Bradley Burnam.
Le premier webinaire en direct est prévu pour le 22 octobre 2025 à 14h00 ET via webcast; les enregistrements et le matériel seront publiés sur le site des relations investisseurs immédiatement après chaque session. Le Blog du Fondateur partagera des mises à jour continues de l'entreprise, des idées de recherche et des perspectives, avec des détails supplémentaires du blog qui seront annoncés plus tard cette semaine.
Turn mentionne trois autorisations FDA pour ses formulations de plaies et de dermatologie et des programmes cliniques en phase avancée dans l'eczéma et l'onychomycose.
Turn Therapeutics (Nasdaq: TTRX) hat eine Aktionärskommunikationsoffensive gestartet, die eine wiederkehrende Webinarreihe und einen Founder Blog des CEO Bradley Burnam umfasst.
Das erste Live-Webinar ist für den 22. Oktober 2025 um 14:00 Uhr ET geplant und wird per Webcast übertragen; Aufzeichnungen und Unterlagen werden sofort nach jeder Sitzung auf der Investor Relations-Website veröffentlicht. Der Founder Blog wird fortlaufende Unternehmensaktualisierungen, Forschungserkenntnisse und Perspektiven teilen, mit weiteren Blog-Details, die später in dieser Woche bekanntgegeben werden.
Turn vermerkt drei FDA-Genehmigungen für seine Wund- und Dermatologieformulierungen und laufende späte Studienprogramme in Ekzem und Onychomykose.
Turn Therapeutics (ناسداك: TTRX) أطلقت مبادرة اتصالات مع المساهمين تتضمن سلسلة ندوات عبر الويب متكررة ومدونة المؤسس من قبل الرئيس التنفيذي برادلي برنان.
الندوة الحية الأولى عبر الويب مقررة في 22 أكتوبر 2025 الساعة 2:00 مساءً بتوقيت شرق الولايات المتحدة عبر البث المباشر؛ سيتم وضع التسجيلات والمواد على موقع علاقات المستثمرين فورًا بعد كل جلسة. ستشارك مدونة المؤسس تحديثات الشركة المستمرة ورؤى البحث ووجهات النظر، مع إعلان تفاصيل إضافية عن المدونة في وقت لاحق من هذا الأسبوع.
Turn تشير إلى ثلاث موافقات FDA على تركيبات الجروح والجسم وتقويمات الجلد وقيد البرامج السريرية في المراحل المتقدمة في الأكزيما والفطريات الظفرية.
Turn Therapeutics (纳斯达克：TTRX) 启动了一项股东沟通倡议，包括定期的网络研讨会系列和由首席执行官 Bradley Burnam 撰写的创始人博客。
第一场现场网络研讨会定于2025年10月22日东部时间下午2:00通过 webcast 举行；每场会后，录像和资料将发布在投资者关系网站上。创始人博客将分享持续的公司更新、研究见解与观点，博客的更多细节将在本周晚些时候公布。
Turn 指出其伤口与皮肤科配方获得了三项 FDA 批准，且在湿疹和甲真菌病领域有长期晚期临床计划。
- None.
- None.
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam.
“It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community,” said Bradley Burnam, Founder and CEO of Turn Therapeutics. “But this company was built by a deeply engaged community, and we intend to continue that conversation as we grow.”
The Founder Blog will publicly share ongoing company updates, research insights, and perspectives on Turn’s growth and innovation. Further details about the blog will be announced later this week. The webinar series will provide live discussion covering ongoing programs, strategic milestones, and upcoming developments. The first live session will take place on Wednesday, October 22, 2025, at 2:00 PM ET via webcast.
Recordings and materials from webinars will be posted immediately following each session to the investor relations section of the company website.
October 22, 2025 live webinar:
Time: 2PM EST
Location: Click here to join
RSVP/Registration: Not required
About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.
Where You Can Find Additional Information
Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://ir.turntherapeutics.com), filings we make with the Securities and Exchange Commission (the “SEC”), our corporate account on the social media platform X (formerly Twitter) (@hexagenhealing), LinkedIn, other social media platforms, webcasts, press releases and conference calls. We use these mediums to communicate with our shareholders and the public about our company and other matters. It is possible that the information that we make available in this manner may be deemed to be material information. We therefore encourage investors and others interested in our company to review this information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. These statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the timing and effectiveness of the Company’s registration statement, the success of development programs, and the Company’s ability to execute its strategic plan. Further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these statements can be found in the Company’s SEC filings. Turn undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact: media@TurnTherapeutics.com
Investor Relations: investors@TurnTherapeutics.com
FAQ
When is Turn Therapeutics (TTRX) hosting its first shareholder webinar?
Do investors need to register to attend the Turn Therapeutics (TTRX) October 22, 2025 webinar?
Where will Turn Therapeutics (TTRX) post webinar recordings and materials after the October 22, 2025 session?
What will CEO Bradley Burnam cover in the new Founder Blog for Turn Therapeutics (TTRX)?
What regulatory progress has Turn Therapeutics (TTRX) announced in the press release?
Which clinical programs did Turn Therapeutics (TTRX) note when launching the webinar series on October 20, 2025?
